- Home
- OMCL vs AMLX Comparison
OMCL vs AMLX Comparison
Compare OMCL & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMCL | AMLX |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OMCL | AMLX |
|---|---|---|
| Price | $46.04 | $18.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $55.83 | $21.56 |
| AVG Volume (30 Days) | 703.6K | ★ 1.6M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $787,309,000.00 | $380,786,000.00 |
| Revenue This Year | $6.77 | N/A |
| Revenue Next Year | $5.22 | N/A |
| P/E Ratio | $186.20 | ★ N/A |
| Revenue Growth | 9.93 | ★ 1612.94 |
| 52 Week Low | $26.85 | $7.48 |
| 52 Week High | $51.84 | $19.15 |
Technical Indicators
Market Signals| Indicator | OMCL | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 64.64 | 61.55 |
| Support Level | $43.34 | $12.17 |
| Resistance Level | $51.62 | $18.88 |
| Average True Range (ATR) | 2.07 | 1.03 |
| MACD | 0.61 | -0.05 |
| Stochastic Oscillator | 89.60 | 65.61 |
Price Performance
Historical ComparisonAbout OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.